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Background: This systematic review examined the effect of non-invasive positive pressure
ventilation (NIPPV) on patient reported outcomes (PROs) and survival for individuals with or
at risk of chronic respiratory failure (CRF).
Methods: Randomised controlled trials (RCTs) and prospective non-randomised studies in those
treated with NIPPV for CRF were identified from electronic databases, reference lists and grey
literature. Diagnostic groups included in the review were amyotrophic lateral sclerosis/motor
neuron disease (ALS/MND), Duchenne muscular dystrophy (DMD), restrictive thoracic disease
(RTD) and obesity hypoventilation syndrome (OHS).
Results: Eighteen studies were included and overall study quality was weak. Those with ALS/
MND had improved somnolence and fatigue as well as prolonged survival with NIPPV. For OHS,
improvements in somnolence and fatigue, dyspnoea and sleep quality were demonstrated,
while for RTD, measures of dyspnoea, sleep quality, physical function and health, mental
and emotional health and social function improved. There was insufficient evidence to form
conclusions regarding the effect of NIPPV for those with DMD.e for Breathing and Sleep, Austin Hospital, PO Box 5555, Heidelberg, Victoria 3084, Australia.
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230 L.M. Hannan et al.Conclusions: This review has demonstrated that NIPPV influences PROs differently depending
on the underlying cause of CRF. These findings may provide assistance to patients and clini-
cians to determine the relative costs and benefits of NIPPV therapy and also highlight areas
in need of further research.
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Non-invasive positive pressure ventilation (NIPPV) is an
established, effective long-term treatment for individuals
with or at risk of chronic hypercapnic respiratory failure
due to a number of heterogeneous conditions. Most
commonly, these conditions include obesity hypo-
ventilation syndrome (OHS), restrictive thoracic diseases
(RTD), chronic obstructive pulmonary disease (COPD) as
well as amyotrophic lateral sclerosis/motor neuron disease
(ALS/MND) and other neuromuscular diseases [1,2] Rapid
expansion in the use of domiciliary NIPPV has been
described in a number of countries [3,4], and it is a
preferred method of providing long-term ventilatory sup-
port (in comparison to negative pressure methods or inva-
sive mechanical ventilation) due to a variety of factorsincluding cost and patient preference as well as a possible
reduction in ventilator associated complications [5e7].
Increasingly, investigators who have evaluated domicil-
iary NIPPV therapy have recognised and emphasised the
reporting of patient reported outcomes (PROs). These
outcome measures generally evaluate the presence or
severity of symptoms and/or determine health-related
quality of life (HRQoL). In general, instruments that eval-
uate HRQoL attempt to measure those aspects of overall
quality of life that can clearly be shown to affect health e
either physical or mental [8]. PROs are considered to be
useful outcome measures in studies involving NIPPV e
particularly where a mortality benefit is unlikely to be
identified. This focus on PROs contrasts earlier studies that
more frequently evaluated physiologic outcome measures,
such as daytime carbon dioxide tension (PaCO2), pulmonary
NIPPV for chronic respiratory failure 231function, or sleep parameters. Unfortunately, the large
range of instruments used in NIPPV studies has made com-
parison of outcomes difficult. In addition, it is likely that
only specific facets of an individual’s health and wellbeing
are influenced by NIPPV, and that these will differ
depending on the underlying disease process that has led to
respiratory failure. This review therefore attempts to
clarify the impact of NIPPV therapy by synthesising sub-
scales of PROs in order to better describe how this therapy
influences specific components of health and wellbeing.
Three previous systematic reviews and a further review
of randomised controlled trials have examined NIPPV for
individuals with hypercapnic respiratory failure secondary
to COPD [9e12]. We conducted a targeted search of elec-
tronic databases from the conclusion of the most recent
review and did not identify additional RCTs that could be
included in a meta-analysis. We therefore elected not to
perform a further evaluation of NIPPV for the treatment of
individuals with COPD.
Two previous systematic reviews have evaluated the role
of long-term NIPPV for individuals with neuromuscular and
chest wall disorders [13], and for ALS/MND [14], but neither
included non-randomised studies, thereby omitting a sig-
nificant number of the studies performed in this area.
Annane et al. concluded that weak but consistent evidence
supports the use of NIPPV to relieve symptoms of chronic
hypoventilation in the short-term for individuals with
neuromuscular and chest wall disorders, while Radunovic
et al. concluded that NIPPV improves or maintains quality of
life in people with ALS/MND. Both reviews concluded that
NIPPV significantly prolongs survival in peoplewithALS/MND.
In spite of a bias towards a positive treatment effect
[15,16], non-randomised studies are able to provide
important data that can assist clinicians. Provided their
limitations are understood, data from well conducted non-
randomised studies evaluating therapy may be similar to
that obtained from RCTs in similar populations [17].
Consideration of non-randomised studies is further neces-
sitated in situations when the likelihood of further RCTs is
low [16]. This is particularly relevant to NIPPV therapy (most
notably for individuals with progressive neuromuscular dis-
eases such as Duchenne muscular dystrophy (DMD) and ALS/
MND) where it may be considered unethical to perform an
RCT when subjects in the control arm would have a poten-
tially life-prolonging treatment withheld [18e20]. Further-
more, no previous review has evaluated the impact of NIPPV
on dyspnoea, sleep quality or examined how therapy in-
fluences specific components of HRQoL. This is significant,
given that many of these outcomes may be perceived by
patients to be more important than survival or physiological
endpoints [21]. We have therefore included both RCTs (for
survival and PRO data) and non-randomised prospective
studies with a repeated measures design (for PRO data) to
examine whether NIPPV improves survival and PROs in in-
dividuals with or at risk of developing chronic respiratory
failure due to ALS/MND, DMD, RTD and OHS.Methods
A systematic review was performed using the methodology
outlined by the Centre for Reviews and Dissemination [22].Search for relevant studies
Databases were searched from the date of their inception
until December 3rd 2012. These included: MEDLINE,
EMBASE, CINAHL, the Centre for Reviews and Dissemina-
tion, The Cochrane Database of Systematic Reviews and the
Cochrane Central Register of Controlled Trials, ACP Journal
Club, Database of Abstracts and Reviews of Effects (DARE),
Health Technology Assessment, and the NHS Economic
Evaluation. We also searched grey literature including:
Proceedings First, Papers First, National Guideline Clearing
House, ProQuest Dissertations and Theses (PDQT). The
electronic searches were supplemented by manually scan-
ning the reference lists from included articles to identify
additional studies that may have been missed during the
search of databases.
Search strategy
Population (disease) specific search terms (obesity hypo-
ventilation syndrome, kyphoscoliosis, muscular dystrophy
and amyotrophic lateral sclerosis) were combined with
intervention specific terms (positive pressure respiration,
artificial respiration, mechanical ventilation, non-invasive)
together with modifications to meet the requirements of
particular databases in all our searches. For a detailed
description of the search strategy please refer to
Supplementary File 1. A flow chart that illustrates the
search strategy and study selection is shown in Fig. 1. Two
researchers reviewed all abstracts and titles identified in
the electronic and manual search independently. Full text
articles were also independently reviewed by two re-
searchers. Disagreements were resolved at each stage of
the search by consensus.
Study selection
Studies were included if they; (1) described participants
with or at risk of respiratory failure due to ALS/MND, DMD,
RTD, or OHS with an indication to commence NIPPV therapy
according to published criteria [23,24]; (2) were an RCT or
prospective study with a repeated measures design; (3)
examined NIPPV (defined as any form or mode of positive
pressure ventilation delivered via a non-invasive interface
[ie nasal, oronasal, total face mask or mouthpiece] for a
minimum of 4 weeks); (4) reported survival or PROs using
standardised instruments evaluating HRQoL, symptoms,
sleep quality, mental health and physical health.
Studies were excluded if they; (1) did not report out-
comes according to diagnostic groups; (2) included partic-
ipants with obstructive lung diseases (COPD, asthma, cystic
fibrosis, bronchiectasis), spinal cord injury, stable (or non-
progressive) neuromuscular diseases, muscular dystrophies
other than Duchenne type and congenital or acquired
central alveolar hypoventilation syndromes, and obstruc-
tive sleep apnoea (except that co-existing in individuals
fulfilling diagnostic criteria for OHS); (3) utilised continuous
positive airway pressure (CPAP), negative pressure venti-
lation, diaphragm or phrenic nerve pacing or invasive
ventilation (delivered via an endotracheal tube or trache-
ostomy); (5) reported only the presence or absence of
Figure 1 Flow diagram of included and excluded studies (PRISMA).
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(6) appeared to report on similar groups of patients
[25,26].Data abstraction
From each selected article, the following information was
abstracted; author, journal, year of publication, study
design, participant characteristics, exclusion criteria,
comparison group (if present for RCTs), use of supplemental
oxygen therapy, other concurrent interventions, method of
NIPPV titration, mode and method of NIPPV, treatment
period, change in PaCO2, drop-outs, compliance (useage),
PRO outcomes, and survival. PRO data were abstracted
from RCTs and prospective studies with a repeated mea-
sures design whereas survival data was only abstracted
from studies with a parallel group RCT design comparing
NIPPV with an appropriate ‘standard care’ (defined as any
or all of; oxygen therapy, medications, supportive care and
lifestyle interventions). When studies reported outcomes at
multiple time-points, we preferentially used data from
between 1 and 6 months (defined as short-term treatment).A number of authors were approached for additional data
[19,25,27e35], and this was received to complement
several reports [19,34,35].Study outcomes
Quality assessment of studies
All articles were assessed using the Quality Assessment Tool
for Quantitative Studies by two investigators indepen-
dently. Discrepancies were resolved by consensus. This tool
provides a global rating and component scores for six
components (selection bias, study design, confounders,
blinding, data collection method and withdrawals and
dropouts) [36,37].
Data analysis
Meta-analyses could not be performed on the included
studies due to the heterogeneity of study design and out-
comes. Two reviewers (LMH and YWC) grouped appropriate
domains (subscales) of PROs independently into 6 discreet
categories; dyspnoea, sleep quality, somnolence and fa-
tigue, mental and emotional health, social functioning, and
NIPPV for chronic respiratory failure 233physical function and health. The methodology has been
described previously [38], and is detailed in Supplementary
File 2. Not all instruments/domains were able to be
assigned into the categories devised.
Only studies that presented repeated measures data for
PROs (mean and standard deviation) were able to be
included in our calculation of effect sizes. These were
calculated for each of the PRO domains as the difference
between the means of the baseline and post-treatment
scores (change from baseline) divided by the standard de-
viation of change. Composite effect sizes and 95% confi-
dence intervals (CI) for each of the combined categories
were then calculated. We used Cohen’s categories
for classifying effect sizes; 0.80 Z large, 0.50 Z medium,
and 0.20 Z small. Further details are provided in
Supplementary File 2.
Results
Our systematic search identified 1533 records after the
removal of duplicates (Fig. 1). After screening titles and
abstracts, 178 studies were retrieved in full text version
and of these, 18 studies were included in our synthesis.
Excluded full-text articles are listed in Supplementary File
3 and reasons for exclusions are summarised in Fig. 1.
The included studies and an overview of study attributes
are displayed in Tables 1 and 2.
Quality assessment
A summary table of the quality assessment of the included
studies is provided in Table 3.
Table 2 demonstrates the number of studies with a
particular design for each condition; only three studies
were RCTs with the remaining being multi-centre (nZ 2) or
single centre prospective cohort studies (n Z 13). Most
included studies rated as strong for data collection methods
and for reporting of withdrawals and dropouts. Selection
bias (10/18), controlling for confounders (15/18) and
blinding (15/18) were frequently rated as weak with the
large number of non-randomised study designs contributing
significantly to these ratings. Global ratings of studies were
most often weak (13/18).
Patient reported outcomes
Twenty-three PROs were used across the included studies
(Table 1 and Supplementary Data File 2). These included
instruments that evaluated sleepiness, dyspnoea, fatigue,
morning headache, mood, anxiety, depression and generic-
and disease-specific health-related quality of life.
Fig. 2(a)e(c) e Forest plots.
Amyotrophic lateral sclerosis/motor neuron disease
Randomised studies
The study by Bourke et al. randomised individuals with ALS/
MND to NIPPV or standard care and demonstrated: median
survival in the NIPPV group of 219 days (range 75e1382
days) vs 171 days (range 1e878 days), improved mentalcomponent summary (MCS) of the SF-36 and all domains of
the Sleep Apnea Quality of Life Index (SAQLI) and Chronic
Respiratory Questionnaire. Repeated measures data for
PROs was unavailable for this study.
Non-randomised prospective studies
Five studies reported outcomes for individuals with ALS/
MND after commencing NIPPV [18,28,30,39,40], and addi-
tional data was provided by one author who originally
grouped their subjects with ALS/MND in a combined
‘neuromuscular disease’ group [35].
Fig. 2(a) summarises the composite effect size according
to our combined categories for PROs. A consistent benefi-
cial effect of NIPPV on somnolence and fatigue was
demonstrated across the included studies. There was no
apparent effect on physical function and health associated
with NIPPV therapy, and dyspnoea, mental and emotional
health and social function were inconsistently influenced
across studies. No data from included studies was available
to evaluate the effect of NIPPV on sleep quality for in-
dividuals with ALS/MND.Duchenne muscular dystrophy
Randomised studies
One randomised controlled trial was identified that re-
ported outcomes for individuals with Duchenne muscular
dystrophy (DMD). Raphael et al. reported results from a
multicentre randomised controlled trial conducted in
France from 1986 until 1991 [41]. The randomly allocated
individuals with DMD and preserved lung function (forced
vital capacity between 20 and 50% of predicted) to
either ‘conventional treatment’ or ‘conventional
treatment þ NIPPV’. The primary outcome was overall
survival and three secondary endpoints (time to occur-
rence of hypercapnia >45 mmHg, time to decrease FVC
below 20% of the value obtained at randomisation, time to
necessary NIPPV ventilation for respiratory failure) were
also examined. Changes in symptoms or HRQoL were not
evaluated in this study. Results were reported for 70
participants (n Z 35 per group) due to a planned interim
analysis demonstrating significantly more deaths in the
NIPPV group. At ‘the reference date’ 8 deaths were
observed in the NIPPV group compared with 2 deaths in
the conventional treatment group. 2-year survival rates
(77% vs 96%) and 3-year survival rates (65% vs 89%)
demonstrated persistent differences between the two
groups. There were no significant differences between the
groups with regard to secondary endpoints.
Non-randomised prospective studies
Only one prospective study including individuals with
DMD and with a repeated measures design evaluating
PROs was identified that reported outcomes specific to
diagnosis. The study by Guilleminault et al. reported pre-
and post- treatment values for the Epworth Sleepiness
Scale (ESS) in only one of three included participants with
DMD. This participant with DMD (who received supple-
mental oxygen in addition to NIPPV treatment) demon-
strated an ESS of 15/24 (at baseline) that fell to 9/24 (at
1 month).
Table 1 Studies included in the systematic review.
Author Study designa Diagnostic
groupb
n Gender
(F:M)
Comparisonc Survivald PROs reported
Bourke* 2006 RCT(single centre,
parallel groups)
ALS/MND NIPPV Z 22
Control Z 19
8:14
9:10
“Standard care” Yes SF-36, CRDQ
SAQLI
Mustfa 2006 PC(single centre) ALS/MND 26 6:20 SF-36, CRDQ, SAQLI
ESS, McGill HRQoL
HADS
Lyall 2001 PC(single centre) ALS/MND 16 1:15 SF-36
ESS
Newsom-Davis 2001 PC(single centre) ALS/MND 9 0:9 ESS, HAD Anxiety score
HAD Depression score
Butz* 2003 PC(single centre) ALS/MND 36 N/R ESS, PSQI
VAS- Sleep quality,
Fatigue scale, Beck’s
Depression Inventory,
von Zersen Mood Scale
Bourke* 2003 PC(single centre) ALS/MND 17 5:12 SF-36, CRDQ, SAQLI, ESS
Raphael 1994 RCT (multicentre,
parallel groups)
DMD NIPPV Z 35
Control Z 35
0:35
0:35
“Conventional
treatment”
Yes
Ferris 2000 PC(single centre) RTD 16 N/R Sadoul Dyspnoea Scale
VAS e Dyspnoea, Morning
headache,
Fatigue, Diurnal drowsiness,
Sleep quality
Borel 2012 RCT(single centre,
parallel groups)
OHS NIPPV Z 19
Control Z 18
11:8
11:7
“Lifestyle
counselling”
No ESS
Murphy 2012 PC(multicentre) OHS 25 14:11 SRI, ESS, FSS
VAS e Fatigue, Sleep
comfort, Physical activity
Piper 2008 PC(single centre) OHS 18 9:9 SF-36, ESS, PSQI
Storre 2006 PC(single centre) OHS 14 2:8 SRI
Windisch 2008 PC(multicentre) Mixed
(OHS)
(RTD)
135
(9)
(29)
2:7
19:10
SF-36, SRI
Tsolaki 2011 PC(single centre) Mixed
(OHS)
(RTD)
(ALS/MND)
101
(28)
(17)
(10)
10:18
6:11
N/R
SF-36, ESS
MRC Dyspnoea Scale
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Nauffal 2002 PC(single centre) Mixed
(RTD)
62
(35)
14:21 SF-36
Borg Dyspnoea scale
Domenech-Clar* 2003 PC(single centre) Mixed
(RTD)
67
(36)
11:17 SF-36
Nickol 2005 PC(single centre) Mixed
(RTD
20
(8)
4:4 ESS
Guilleminault* 1998 PC(single centre) Mixed
(DMD)
20
(3)
0:3 ESS
* These studies fulfilled the inclusion criteria for the review however missing or unavailable data have not allowed incorporation into the calculation of composite effect sizes.
RCT e randomised controlled trial, PC e prospective cohort, NIPPV e non-invasive positive pressure ventilation, AVAPS e average volume assured pressure support, CPAP e continuous
positive airway pressure, M e male, F e female, PRO e patient reported outcome, ALS/MND e amyotrophic lateral sclerosis/motor neurone disease, OHS e obesity hypoventilation
syndrome, RTD e restrictive thoracic disease, DMD e Duchenne muscular dystrophy, S mode e spontaneous mode, T mode e timed mode, S/T mode e spontaneous/timed mode, A/C
mode e assist/control mode, SRI e Severe Respiratory Insufficiency Questionnaire, SF-36 e Medical Outcomes Study Short Form Health Survey, SAQLI e Calgary Sleep Apnea Quality of Life
Index, FSS e Fatigue Severity Score, PSQI e Pittsburgh Sleep Quality Index, SSS e Stanford Sleepiness Score, ESS e Epworth Sleepiness Scale, FSS e Fatigue Severity Scale, CRDQ e Chronic
Respiratory Disease Questionnaire, HADS e Hospital Anxiety Depression Score, MRC e Medical Research Council, McGill HRQoL e McGill Quality of Life Questionnaire, VAS e Visual
Analogue Scale.
a Study design was determined by the reviewers and is reported according to the method in which the data from the study was analysed in this review (and not necessarily how the
authors of the study reported the study design) e for example; the study by Murphy et al. was reported by the authors to be a randomised controlled trial however in order to attempt to
answer this review question, the data was analysed as a prospective cohort study (with repeated measures) and therefore has been reported in this manner.
b Diagnostic groups listed include only those where results were reported according to specific diagnosis e for example if a study reported results for a group with ‘neuromuscular
disease’ but did not separate outcomes according to a specific diagnosis (ie Duchenne muscular dystrophy or amyotrophic lateral sclerosis), these groups/diagnoses were not included in
our analysis.
c Only comparison group data that is included in this review is reported.
d Only randomised controlled trials were evaluated for survival analysis.
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Table 2 Overview of study attributes by diagnostic group.
Author n % Not analyseda NIPPV Titration method (site;
technique)b
Co-interventionsc Treatment
intervald
ALS/MND
Bourke* 2006 NIPPV Z 22 0 Pressure; S/T mode Inpatient; ABG, Overnight
monitoring
Riluzole, Vaccinations, Airway
clearance techniques,
Palliative care
Control Z 19
Mustfa 2006 26 33.3% Pressure; mode not
described
Inpatient; ABG, Overnight
monitoring
Phone support 3 months
Lyall 2001 16 6.3% Pressure; mode not
described
Uncertain; ABG Airway clearance techniques 1-month
Tsolaki 2011 10 9.9%# Pressure; S/T mode Inpatient, Clinical, ABG Inpatient training, home visits 3 months
Newsom-Davis 2001 9 0 Not described Inpatient; not described Clinic visits 1.5 months
Butz* 2003 36 47.2% Pressure; various Uncertain; Clinical, ABG 1-month
Bourke* 2003 17 41.2% Pressure; S/T mode Inpatient; ABG, Overnight
monitoring
Airway clearance techniques N/R
DMD
Raphael 1994 NIPPV Z 35 0 Volume; A/C mode Inpatient; ABG Antibiotics, Physiotherapy
Control Z 35
Guilleminault* 1998 3 0# Pressure; T mode Uncertain; PSG Supplemental oxygen (n Z 1),
Home visits
1-month
RTD
Nauffal 2002 35 0# Pressure; Inpatient; ABG Supplemental oxygen (n Z 19),
Phone support, Clinic visits
3 months
Windisch 2008 29 37.0%# Pressure and Volume;
A/C mode
Inpatient; Clinical, ABG Inpatient re-assessments 1-month
Tsolaki 2011 17 9.9%# Pressure; S/T mode Inpatient, Clinical, ABG Inpatient training, home visits 3 months
Domenech-Clar* 2003 36 32.8%# Pressure; Inpatient; ABG Supplemental oxygen (n Z 11),
Phone support
3 months
Nickol 2005 8 0# Pressure; Inpatient; ABG, Overnight
monitoring
Supplemental oxygen (n Z ?) 3 months
Ferris 2000 16 0 Pressure; T mode Volume;
A/C mode
Inpatient; Clinical, ABG,
Overnight monitoring
Supplemental oxygen (n Z 6),
Phone support
6 months
OHS
Borel 2012 NIPPV Z 19 5.4% Pressure; S/T mode Inpatient; not described 1-month
Control Z 18
236
L.M
.
H
a
n
n
a
n
e
t
a
l.
Murphy 2012 25 8.0% Pressure; S/T mode Inpatient; Overnight
monitoring
3 months
Piper 2008 18 0 Pressure; S mode Uncertain; PSG Supplemental oxygen (n Z 4) 3 months
Storre 2006 14 28.6% Pressure; S/T mode Uncertain; Clinical,
Overnight
monitoring
1.5 months
Tsolaki 2011 28 9.9%# Pressure; S/T mode Inpatient, Clinical, ABG Inpatient training, home visits 3 months
Windisch 2008 9 37.0%# Pressure and Volume;
A/C mode
Inpatient; Clinical, ABG Inpatient re-assessments 1-month
* These studies fulfilled the inclusion criteria for the review however missing or unavailable data have not allowed incorporation into the calculation of composite effect sizes.
# For studies with mixed cohorts, the % not analysed is the value for the overall study population and is not specific for diagnosis.
NIPPV e non-invasive positive pressure ventilation, AVAPS e average volume assured pressure support, CPAP e continuous positive airway pressure, M e male, F e female, PRO e patient
reported outcome, ALS e amyotrophic lateral sclerosisZ motor neurone disease, OHS e obesity hypoventilation syndrome, RTD e restrictive thoracic disease, DMD e Duchenne muscular
dystrophy, S mode e spontaneous mode, T mode e timed mode, S/T mode e spontaneous/timed mode, A/C mode e assist/control mode, SRI e Severe Respiratory Insufficiency
Questionnaire, SF-36 e Medical Outcomes Study Short Form Health Survey, SAQLI e Calgary Sleep Apnea Quality of Life Index, FSS e Fatigue Severity Score, PSQI e Pittsburgh Sleep Quality
Index, SSS e Stanford Sleepiness Score, ESS e Epworth Sleepiness Scale, FSS e Fatigue Severity Scale, CRDQ e Chronic Respiratory Disease Questionnaire, HADS e Hospital Anxiety
Depression Score, MRC e Medical Research Council, McGill HRQoL e McGill Quality of Life Questionnaire, VAS e Visual Analogue Scale.
a % Not analysed includes those not analysed due to reported deaths, drop-outs or ‘lost to follow-up’ at the treatment interval examined in this review (where analysis not intention-to-
treat).
b Site; Inpatient (Zhospital admission), Outpatient (Zcommunity), Technique; Clinical (Zclinical assessment of symptoms and comfort but may include additional simple daytime
monitoring (using pulse oximetry or transcutaneous CO2 alone or in combination); ABG (Zadjustment using PaCO2  PaO2 from arterial sampling (includes arterialised ear lobe samples);
Overnight monitoring (Zuse of limited overnight monitoring such as pulse oximetry, transcutaneous CO2, respiratory polygraphy); PSG (Zuse of full polysomnography).
c As identified in this review.
d Some studies reported outcomes at multiple time points, the treatment intervals listed here are those that have been used in the analysis and generally represent ‘short-term’
treatment periods.
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Table 3 Quality assessment.
Study Selection
bias
Study
design
Confounders Blinding Data
collection
method
Withdrawals
and dropouts
Total
18 Z Weakest
possible
6 Z Strongest
possible
Global
rating
Bourke 2006 Moderate Strong Strong Weak Strong Strong 9 Moderate
Mustfa 2006 Moderate Moderate Weak Weak Strong Strong 12 Weak
Lyall 2001 Weak Moderate Weak Weak Strong Strong 13 Weak
Newsom-Davis 2001 Weak Moderate Weak Weak Strong Strong 13 Weak
Butz 2003 Weak Moderate Weak Weak Strong Moderate 14 Weak
Bourke 2003 Weak Moderate Weak Weak Strong Weak 15 Weak
Raphael 1994 Strong Strong Strong Weak Strong Strong 8 Moderate
Ferris 2000 Weak Moderate Weak Weak Weak Strong 15 Weak
Borel 2012 Moderate Strong Moderate Moderate Strong Strong 9 Strong
Murphy 2012 Moderate Moderate Weak Moderate Strong Strong 11 Moderate
Piper 2008 Moderate Moderate Weak Weak Strong Strong 12 Weak
Storre 2006 Moderate Moderate Weak Moderate Strong Moderate 12 Moderate
Windisch 2008 Moderate Moderate Weak Weak Strong Moderate 13 Weak
Tsolaki 2011 Weak Moderate Weak Weak Strong Strong 13 Weak
Nauffal 2002 Weak Moderate Weak Weak Strong Strong 13 Weak
Domenech-Clar 2003 Weak Moderate Weak Weak Strong Moderate 14 Weak
Nickol 2005 Weak Moderate Weak Weak Moderate Strong 14 Weak
Guilleminault 1998 Weak Moderate Weak Weak Strong Weak 15 Weak
Total score is the sum of the six component scores where WeakZ 3 points, ModerateZ 2 points and StrongZ 1 point. Global ratings are
determined according to the following schema; no Weak ratingsZ Strong, 1 Weak ratingZ Moderate, 2 or more Weak ratingsZ Weak.
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Randomised studies
No randomised controlled trials were identified that re-
ported outcomes according to diagnosis for individuals with
RTD.
Prospective cohort studies
We included the study by Ferris et al. in addition to four
studies with mixed cohorts that reported outcomes ac-
cording to diagnostic group in our calculation of composite
effect sizes [19,35,42,43] Additional data was forthcoming
for two reports to enable their inclusion in the calculations
[19,35].
Fig. 2(b) summarises the composite effect size according
to our combined categories for PROs. A consistent benefi-
cial effect of NIPPV on dyspnoea, sleep quality, physical
function and health, mental and emotional health and so-
cial function was demonstrated across included studies.
Somnolence and fatigue also improved in most studies
where it was evaluated. There appeared to be a relation-
ship between effect size and study quality with ‘weaker’
studies tending to report larger effect sizes although it
should be noted that all studies evaluating individuals with
RTD were rated as weak.Obesity hypoventilation syndrome
Randomised studies
The review identified one parallel group RCT including in-
dividuals with OHS. Borel et al. randomly allocatedindividuals with ‘mild OHS’ to treatment with NIPPV or a
comparison group that received lifestyle counseling [44].
The study evaluated ambulatory obese individuals
(BMI>30 kg/m2) with a screening daytime arterial blood gas
sample to identify those with hypercapnia (initially defined
as PaCO2  45 mmHg, however the investigators altered the
protocol to include those with PaCO2 43e45 mmHg) and
invited these individuals to participate. Despite random-
isation, the NIPPV group was older (58  11 years vs 54  6
years) and had a higher baseline PaCO2 (48.0  4.5 mmHg vs
45  3.0 mmHg) than the control group. Pressure-limited
NIPPV therapy in spontaneous-timed (S/T) mode was
commencedduring an inpatient stay for all those in theNIPPV
group. After 1 month of NIPPV there was a greater reduction
in daytime PaCO2, AHI and severity of overnight disturbances
in SpO2 in the NIPPV group compared with control, however
there was no significant difference in daytime somnolence
according to the ESS (control mean difference2.1 (4.5 to
0.4) vs NIPPV mean difference 3.4 (6.0 to 0.8)).
Other included studies evaluated the effect of NIPPV on
individuals with OHS in comparison to continuous positive
airway pressure (CPAP) [34], and average volume assured
pressure support (AVAPS) NIPPV [45,46] While treatment
allocation was randomly assigned in these studies (parallel
group, and crossover), it was determined to analyse these
studies using only the conventional (fixed) NIPPV data as a
prospective cohort with repeated measures in order to best
address the review question.
Prospective cohort studies
In addition to these three studies [34,45,46], two others
with mixed cohorts (previously described) included
Figure 2 Forest plots of composite effect sizes (with 95% confidence intervals) for PROs in studies evaluating the effect of NIPPV
in individuals with (a) ALS/MND; (b) RTD and; (c) OHS.
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diagnosis [19,35].
Fig. 2(c) summarises the composite effect size according
to our combined categories for PROs. There was a consis-
tent beneficial effect of NIPPV on somnolence and fatigue
demonstrated across all included studies. Other PRO cate-
gories inconsistently improved in association with NIPPV
therapy. It should be noted that the study by Storre et al.
enrolled those who had ‘failed CPAP therapy’ based on
physiological parameters and therefore a partial treatment
effect on PROs may have influenced the baseline assess-
ments in this study.Discussion
This review has demonstrated considerable differences in
the manner in which NIPPV influences the health and
wellbeing of individuals that require this therapy. Most
striking is the finding that of the categories defined in this
review, only somnolence and fatigue were demonstrated to
consistently improve across studies involving individuals
with ALS/MND. Composite effect sizes were generally large
but ranged from 0.44 to 1.91. While previous reviews have
concluded that “NIPPV significantly improves and maintains
quality of life” for those with ALS/MND [14], our results
suggest that the spectrum of benefits from NIPPV is in fact
much narrower. The apparent lack of a consistent benefit in
other categories defined in this review may be reflection of
the rapidly progressive nature of ALS/MND, in which any
initial gains in these areas are quickly negated by disease
progression, or alternatively this may indeed indicate a lack
of benefit of NIPPV on these domains. We speculate that
the presence of somnolence and fatigue may identify an
individual that is more likely to notice the benefits of
NIPPV, and this may have important implications in deter-
mining adherence and tolerability with ongoing NIPPV
therapy. Regarding survival outcomes, our findings are
consistent with those in previous reviews, with the study by
Bourke et al. convincingly demonstrating that overall there
is prolonged survival associated with NIPPV therapy for
those with ALS/MND [29]. For the subgroup with severe
bulbar involvement, a survival benefit was not demon-
strated in this study, however there were benefits in PRO
outcomes associated with NIPPV therapy.
Also notable in our review was the paucity of prospec-
tive studies evaluating NIPPV for individuals with DMD, with
the study by Raphael et al. remaining the largest prospec-
tive study in this population [41]. The excess mortality
demonstrated with early NIPPV in this study is not
adequately explained by differences in the proportion of
left ventricular dysfunction between groups as most of the
deaths appeared to be related to retention of tracheo-
bronchial secretions. The authors suggested that the use of
NIPPV may have created a false sense of security for this
group and thus a less urgent response to deteriorations. It is
certainly likely that there were differences between the 17
centres in the management and support of those
commencing NIPPV and this may have contributed to the
excess mortality. We wonder whether a similar study uti-
lising current NIPPV therapy, community supports and
airway clearance techniques would replicate the amount ofharm associated with early NIPPV therapy. Despite this
negative study for NIPPV therapy in DMD, it remains widely
accepted that NIPPV does in fact improve survival in in-
dividuals with DMD once hypercapnic respiratory failure
develops, and current guideline recommendations are in
keeping with this [23,47] Indeed there may be a role for
earlier institution of NIPPV for those with DMD, with the
study reported by Ward et al. demonstrating in a mixed
cohort with congenital neuromuscular and chest wall dis-
orders that evidence of nocturnal hypoventilation appears
to identify individuals that are at high risk of developing
daytime hypercapnia [27]. These individuals warrant at
least close clinical assessment and observation, and a low
threshold for commencement of NIPPV. Unfortunately, due
to its mixed population, this study is limited in its ability to
guide specific recommendations for individuals with DMD.
Of the groups included in this review, those with RTD
appear to obtain the widest spectrum of benefit in PRO
categories after short-term therapy with NIPPV. Dyspnoea,
sleep quality, physical function and health, mental and
emotional health and social function were demonstrated to
improve in all included studies. Somnolence and fatigue
also appeared to improve in most studies where it was
evaluated. These results for individuals with RTD, who are
more likely to have a stable disease process, provide an
interesting contrast to those with ALS/MND. However, while
the composite effect sizes in these studies were generally
large, it did appear that ‘weaker’ studies tended to report
larger effect sizes, which suggests that these may over-
estimate the true magnitude of effect.
Although less consistent than RTD, those with OHS also
appear able to benefit across a relatively wide spectrum of
PRO categories after commencing NIPPV. Somnolence and
fatigue consistently improved in studies involving in-
dividuals with OHS and dyspnoea and sleep quality also
improved, with the exception of the study by Storre et al.
that may have included participants partially treated with
CPAP. Mention should be made however, of the study by
Borel et al. which did not demonstrate a significant dif-
ference in the Epworth Sleepiness Scale after 1 month of
NIPPV [44]. This apparent lack of benefit on somnolence
may reflect the population studied which had relatively
‘mild’ OHS based on a lower threshold for hypercapnia
(43 mmHg) and recruitment of ambulatory outpatients
from a newspaper advertisement. In contrast, the other
studies evaluating individuals with OHS included partici-
pants who were more hypercapnic [19,34,35,46] or who had
‘failed’ CPAP therapy [45]. The shorter treatment interval
in the study by Borel et al. may also have contributed to the
apparent lack of effect. Although a 1 month period of NIPPV
therapy is sufficient to alter ABG parameters in those with
OHS [48,49] changes in PROs may require a longer period of
acclimatisation to NIPPV.
This review has a number of limitations that require
consideration. We have touched on the issues of evaluating
non-randomised studies previously and we again highlight
the risks of drawing concrete conclusions from these
studies due to the likelihood of bias. Overall, the quality of
studies in this area was weak, with studies limited pre-
dominantly by selection bias, presence of confounders and
lack of blinding. In particular, we suspect that co-
interventions such as the method of initial NIPPV
NIPPV for chronic respiratory failure 241titration, access to 24-h telephone support, use of home
visits and provision of airway clearance techniques may
have an influence on some PRO measures. Many of these co-
interventions are routinely applied during the transition to
domiciliary NIPPV therapy, yet the variation in practice
demonstrated across the studies included in this review
hints at a lack of robust evidence to support their routine
use.. Their impact on the reported outcomes is therefore
unknown but may have been significant and further studies
are required to clarify the magnitude of any effect. In
addition to study quality, we acknowledge that the exclu-
sion of non-English language articles was not optimal,
however, cost and logistical constraints limited our ability
to perform translations. Finally, our method of producing
composite effect sizes required the review team to make a
number of judgements and assumptions regarding the
grouping of instruments that we felt measured similar
constructs. In calculating our composite effect sizes we
used conservative measures of correlation between in-
struments in addition to the small amount of published data
comparing instruments in our study populations. We have
provided a detailed description of the process for producing
the composite effect sizes in Supplementary File 2 in order
that our methods are available for review.Conclusion
The data regarding the effects of NIPPV on individuals with
or at risk of chronic respiratory failure is generally weak.
However, there is consistent evidence of benefit for in-
dividuals with ALS/MND for both survival and measures of
somnolence and fatigue. For those with OHS, NIPPV also
appears likely to improve measures of somnolence and fa-
tigue, dyspnoea and sleep quality, while for those with
RTD, measures of dyspnoea, sleep quality, physical function
and health, mental and emotional health and social func-
tion were consistently reported to improve. There was
insufficient data to form conclusions regarding DMD, how-
ever based on published data, there remains no prospective
evidence to support NIPPV therapy for DMD in those without
evidence of hypoventilation.
This review has identified areas for further research.
Previous authors have suggested that further RCTs in this
area are required [13], however ethical considerations are
likely to be a significant barrier. We would encourage pro-
spective studies examining how the presence of somno-
lence and fatigue may influence the tolerability and
compliance with NIPPV for those with ALS/MND in order to
better clarify the significance of these symptoms. There is
also a need for more rigorous efforts to prospectively
evaluate NIPPV for individuals with DMD in order to better
define and refine this therapy. In addition, an examination
of the role that co-interventions may play towards
improving outcomes for individuals using long-term NIPPV is
necessary. Specifically, evaluating the roles of airway
clearance techniques, advanced care planning and
nocturnal monitoring (including polysomnography) in the
provision of NIPPV therapy should be a research priority in
this area. Finally, investigators considering the use of PROs
in studies involving NIPPV are encouraged to carefully
examine the instruments they choose in order to ensureappropriate domains are included that can best identify a
treatment effect, if present.Conflict of interest
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